Myriad says meta-analysis supports prognostic performance of Prolaris biopsy test in localized prostate cancer

Myriad Genetics, Inc.

Myriad Genetics, Inc.

MYGN

0.00
  • Myriad Genetics flagged new peer-reviewed meta-analysis data supporting its Prolaris Biopsy Test as an added prognostic tool in localized prostate cancer.
  • Analysis pooled 14 studies covering 8,478 patients, with individual participant data for 7,924 patients.
  • Prolaris combined clinical risk score showed significant prognostic value for distant metastasis risk, prostate cancer-specific mortality across NCCN risk groups.
  • Data indicate incremental risk-stratification beyond established clinical tools such as Gleason score, CAPRA score, NCCN risk group.
  • Results may support broader clinical adoption for active surveillance selection, treatment decisions, escalation in localized prostate cancer.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Myriad Genetics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202607020905PRIMZONEFULLFEED9755977) on July 02, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.